ArticleAdvances in pharmacological and pharmaceutical sciences2021
Acetylcholinesterase Inhibitory and Antioxidant Activity of the Compounds Isolated from
Article in Advances in pharmacological and pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Design, Synthesis, X-Ray Crystallographic Characterization, Anticholinesterase and Antioxidant Evaluation, and Molecular Modeling of Novel Dispiroindene-Pyrrolidine Derivatives as Multifunctional Anti-Alzheimer Agents.Drug development research · 2026Article
- Isolation and identification of hasubanan alkaloids having anti-cholinesterase and antioxidant activity from the stem Stephania japonica.BMC complementary medicine and therapies · 2026Article
- New benzimidazole-alkanesulfonate conjugates as cholinesterase inhibitors with in vitro and in silico validation.Scientific reports · 2026Article
- Syringaldehyde Ameliorates Cognitive Dysfunction in APP/PS1 Mice by Stabilizing the NLRP3 Pathway.Molecular neurobiology · 2025Article
- A holistic visualization for quality of Chinese materia medica: Structural and metabolic visualization by magnetic resonance imaging.Journal of pharmaceutical analysis · 2024Review
- Exploring the mechanism of action ofHeliyon · 2024Article
- Comprehensive spectroscopic and computational insight into the binding of vanillin with human transferrin: targeting neuroinflammation in Alzheimer's disease therapeutics.Frontiers in pharmacology · 2024Article
- Therapeutic Potential and Predictive Pharmaceutical Modeling of Stilbenes inPharmaceutics · 2023Review
- Adding New Scientific Evidences on the Pharmaceutical Properties ofPlants (Basel, Switzerland) · 2023Article
- Conventional methods and future trends in antimicrobial susceptibility testing.Saudi journal of biological sciences · 2023Review
- Overview of the Role of Vanillin in Neurodegenerative Diseases and Neuropathophysiological Conditions.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.